Systemic treatment of elderly patients with NSCLC: Results of a German prospective observational study.

e19052 Background: In various trials designed especially for elderly patients with NSCLC stage IIIB/IV (≥ 70 years) survival and QoL benefit from single or combination chemotherapy could be demonstrated. Treatment decision concerning single or combination chemotherapy should be based on performance status and co-morbidities. We prospectively evaluated treatment behaviours for elderly patients in Germany in clinical practice. Methods: Between November 2009 and October 2013 a total of 253 patients were included. Participating centres were limited to 20 patients and had to enroll consecutive NSCLC patients ≥ 70 years with stage IIIB or IV. Co-morbidities accrued prospectively in questionnaire and weighted according to Charlson Score. Results: Median age was 75.5 years ranging from 70 through 92 years. 75% of all patients were male. Co-morbidities: 2% none, 5% one, 15% two, 24% three and 55% with more than three concomitant diseases. Most common co-morbidities were hypertension (69%), COPD (42%) and diabetes ...